MX2019006938A - Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. - Google Patents

Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.

Info

Publication number
MX2019006938A
MX2019006938A MX2019006938A MX2019006938A MX2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A
Authority
MX
Mexico
Prior art keywords
methods
pulmonary hypertension
compositions
treatment
vasodilator
Prior art date
Application number
MX2019006938A
Other languages
English (en)
Inventor
Donovan Martin
Weers Jeffrey
Smyth Hugh
Curtis Robert
frost Adaani
Shreeniwas Revati
Romero Alain
Xu Zhen
Original Assignee
Respira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respira Therapeutics Inc filed Critical Respira Therapeutics Inc
Publication of MX2019006938A publication Critical patent/MX2019006938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente métodos para tratar hipertensión pulmonar. Los métodos incluyen administrar a un sujeto en necesidad del mismo una cantidad efectiva de un vasodilatador, en donde el vasodilatador se administra al sujeto por la vía de la inhalación pro re nata o como sea requerido utilizando un inhalador portátil. En algunas modalidades, el vasodilatador es un inhibidor PDE5. También se describen composiciones farmacéuticas para administración pro re nata de los vasodilatadores.
MX2019006938A 2016-12-14 2017-12-14 Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. MX2019006938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662434185P 2016-12-14 2016-12-14
PCT/US2017/066519 WO2018112258A1 (en) 2016-12-14 2017-12-14 Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Publications (1)

Publication Number Publication Date
MX2019006938A true MX2019006938A (es) 2019-09-06

Family

ID=60888760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006938A MX2019006938A (es) 2016-12-14 2017-12-14 Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.

Country Status (10)

Country Link
US (4) US10912778B2 (es)
EP (1) EP3554507A1 (es)
JP (2) JP2020502121A (es)
CN (1) CN110381951A (es)
AU (2) AU2017378409A1 (es)
BR (1) BR112019012251A2 (es)
CA (1) CA3046025A1 (es)
MX (1) MX2019006938A (es)
RU (1) RU2019121646A (es)
WO (1) WO2018112258A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9789126B2 (en) 2012-12-21 2017-10-17 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
CA3023257A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
WO2018132371A2 (en) * 2017-01-10 2018-07-19 United Therapeutics Corporation Methods and compositions for treating pulmonary hypertension
JP2022526621A (ja) * 2019-04-10 2022-05-25 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 心血管機能障害の性別依存性処置のための方法及び材料
WO2020251983A1 (en) * 2019-06-10 2020-12-17 Respira Therapeutics, Inc. Carrier-based formulations and related methods
CN112569210B (zh) * 2019-09-27 2023-09-15 盈科瑞（天津）创新医药研究有限公司 一种吸入用马昔腾坦溶液及其制备方法
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
AU2021463728A1 (en) 2021-09-10 2024-04-18 Justus-Liebig-Universität Giessen Inhaled iloprost for treatment as needed in pulmonary hypertension

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
US4883812A (en) 1976-08-17 1989-11-28 Burroughs Wellcome Co. Treatment of hypertension using prostacyclin
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DE3417638A1 (de) 1984-05-10 1985-11-14 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur bestimmung geringer stoffmengen von arzneimitteln, von koerpereigenen oder anderen chemischen substanzen in biologischem material
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
EP1049695B1 (de) 1997-11-12 2002-02-13 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
ES2310166T3 (es) 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
EP1219609B1 (en) 1999-09-16 2007-04-04 Tanabe Seiyaku Co., Ltd. Aromatic nitrogenous six-membered ring compounds
CN1264574C (zh) 2000-09-06 2006-07-19 田边制药株式会社 口服制剂
EP1373192A1 (en) 2001-03-28 2004-01-02 Pfizer Limited N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20040077624A1 (en) 2002-05-23 2004-04-22 Pfizer Inc. Novel combination
JP2007503393A (ja) * 2003-08-22 2007-02-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｃｏｐｄ及び肺高血圧の治療方法
CA2612917A1 (en) 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
DK1993557T3 (en) 2006-02-03 2015-12-07 Actelion Pharmaceuticals Ltd NOVEL epoprostenol DEFINITION AND MANUFACTURING METHOD THEREOF
JP5797376B2 (ja) 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
ES2630407T3 (es) 2007-12-17 2017-08-21 United Therapeutics Corporation Procedimiento mejorado para preparar treprostinil, el principio activo en Remodulin®
JP2011507968A (ja) 2007-12-27 2011-03-10 エイヤーズ ファーマシューティカルズ、インク． エアロゾル化ニトライトおよび一酸化窒素供与性化合物ならびにそれらの使用
EP2280696B9 (en) 2008-03-18 2016-01-13 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
WO2009115235A1 (en) 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
JP5764061B2 (ja) 2008-08-13 2015-08-12 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ マシテンタン含有治療用組成物
CN104326991A (zh) 2009-06-26 2015-02-04 日本新药株式会社 晶体
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
WO2011037613A1 (en) 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
EP2566478A4 (en) 2010-05-03 2014-04-30 Tsh Biopharm Corp Ltd PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
EP2648788B1 (en) 2010-12-07 2017-08-09 Respira Therapeutics, Inc. Dry powder inhaler
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2015127258A2 (en) 2014-02-21 2015-08-27 Respira Therapeutics, Inc. Powder inhaler, system and methods
JP6890540B2 (ja) * 2015-01-13 2021-06-18 バイバス・インコーポレイテッドＶｉｖｕｓ， Ｉｎｃ． 肺高血圧症のための併用療法
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Also Published As

Publication number Publication date
AU2022256085A1 (en) 2022-11-17
US20220347183A1 (en) 2022-11-03
BR112019012251A2 (pt) 2019-11-05
CA3046025A1 (en) 2018-06-21
US20220079949A1 (en) 2022-03-17
JP2023036678A (ja) 2023-03-14
AU2017378409A1 (en) 2019-07-04
EP3554507A1 (en) 2019-10-23
CN110381951A (zh) 2019-10-25
US20200093830A1 (en) 2020-03-26
RU2019121646A (ru) 2021-01-15
JP2020502121A (ja) 2020-01-23
RU2019121646A3 (es) 2021-03-17
US10912778B2 (en) 2021-02-09
WO2018112258A1 (en) 2018-06-21
US11491161B2 (en) 2022-11-08
US11491160B2 (en) 2022-11-08
US20210205318A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
MX2019006938A (es) Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
ZA202103404B (en) Composition and method for treating the lungs
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
AU2017265011B2 (en) Methods of administering high concentrations of nitric oxide
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
NO20072920L (no) Kombinasjon av metylxantinforbindelser og steroider for a behandle kroniske respirasjonssykdommer
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
RU2017134443A (ru) Способ лечения с применением традипитанта
EA201791780A1 (ru) Ингаляционный раствор тиотропия для небулайзерного распыления
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
EA201370230A1 (ru) Новые ингибиторы rock
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
MX2021014343A (es) Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.
EA202091376A1 (ru) Нерацемические смеси и их применения
WO2018090004A3 (en) Tuberculosis therapeutic compounds and methods
UA83932U (ru) Способ лечения больных хроническим обструктивным заболеванием легких, совмещенным с неалкогольным стеатогепатитом